Company Description
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration.
The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors.
The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases.
Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies.
Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Craig C. Parker M.B.A. |
Contact Details
Address: 171 Oyster Point Blvd, Suite 400 South San Francisco, California 94080 United States | |
| Phone | 650-475-2820 |
| Website | surrozen.com |
Stock Details
| Ticker Symbol | SRZN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001824893 |
| CUSIP Number | 86889P109 |
| ISIN Number | US86889P2083 |
| Employer ID | 30-1374889 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig C. Parker M.B.A. | Chief Executive Officer, President and Director |
| Charles Williams | Chief Financial Officer, Chief Operating Officer and Corporate Secretary |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Roeland Nusse Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Calvin Kuo M.D., Ph.D. | Co-Founder and Member of Scientific Advisor |
| Dr. Li Yang Ph.D. | Executive Vice President of Research |
| Esther Jhun | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | ARS | Filing |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 19, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 19, 2024 | D | Notice of Exempt Offering of Securities |
| Apr 18, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 10, 2024 | 10-K | Annual Report |